Indian authorities have stepped up scrutiny of drugmakers in recent months after some cough syrups made in the country were linked to the deaths of at least 95 children overseas.

Indian authorities have stepped up scrutiny of drugmakers in recent months after some cough syrups made in the country were linked to the deaths of at least 95 children overseas.

Recent risk-based inspections of 162 factories and 14 public laboratories found issues including "poor documentation, lack of process and analytical validations, absence of self-assessment, absence of quality failure investigation, (and) absence of internal product quality review," it said in a statement. It also flagged an absence of raw materials testing, a lack of measures to avoid cross-contamination, an absence of professionally qualified employees, and faulty design of manufacturing and testing areas.

The violations related to manufacturing and laboratory practices at drugmaker Riemann Labs, whose cough syrup was linked to the deaths of children in Cameroon, a government health official told Reuters. Riemann Labs did not respond to requests for comment from Reuters. It is the fourth Indian cough syrup maker to stop production after regulators found lapses.

Rajesh Bhatia, one of the three directors at Riemann Labs, had told Reuters previously he was not aware of the matter.

Regulators inspected the company's production unit in Madhya Pradesh state and issued a notice after finding lapses, said Sudam Khade, the state's drugs controller.

"Some violations in good manufacturing practices and good lab practices were found," Khade said, without specifying what the violations were.

Samples of all of the company's products had been sent for testing and further action would be decided based on the results, Khade said.

India's $41 billion pharmaceutical industry is one of the biggest globally, known for providing cheaper alternatives to western products, but the recent cough syrup-related deaths have hurt that image.

The government has stopped production at four drugmakers so far after contaminants were flagged in their cough syrups by agencies including the World Health Organisation. The companies deny any wrongdoing.

The ministry said it has upgraded 'Good Manufacturing Practices' under the Drugs and Cosmetics Rules to check the deficiencies found during the inspections.

The upgrade includes the introduction of quality risk management, product quality review, supplier audit and approval, and validation of equipment.

Large drugmakers have been given six months and small manufacturers 12 months to transition to the upgraded manufacturing requirements, the ministry said.

India has tightened its testing of cough syrup exports since June, making it mandatory for companies to obtain a certificate of analysis from a government laboratory before exporting products.

Reuters